These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 17401463)

  • 21. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter hypermethylation of death-associated protein kinase gene in cholangiocarcinoma.
    Liu XF; Kong FM; Xu Z; Yu SP; Sun FB; Zhang CS; Huang QX; Zhou XT; Song ZW
    Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):407-11. PubMed ID: 17690039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.
    Luebeck EG; Curtius K; Hazelton WD; Maden S; Yu M; Thota PN; Patil DT; Chak A; Willis JE; Grady WM
    Clin Epigenetics; 2017; 9():113. PubMed ID: 29046735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma.
    Zou H; Osborn NK; Harrington JJ; Klatt KK; Molina JR; Burgart LJ; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):830-4. PubMed ID: 15824152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
    Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
    Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.
    Hasebe K; Yamazaki K; Yamaguchi J; Kokuryo T; Yokoyama Y; Miyata K; Fukaya M; Nagino M; Ebata T
    Lab Invest; 2022 Aug; 102(8):885-895. PubMed ID: 35279702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DAPK promoter hypermethylation in tissues and body fluids of oral precancer patients.
    Liu Y; Zhou ZT; He QB; Jiang WW
    Med Oncol; 2012 Jun; 29(2):729-33. PubMed ID: 21516484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammation and Barrett's carcinogenesis.
    Poehlmann A; Kuester D; Malfertheiner P; Guenther T; Roessner A
    Pathol Res Pract; 2012 May; 208(5):269-80. PubMed ID: 22541897
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic patterns in the progression of esophageal adenocarcinoma.
    Eads CA; Lord RV; Wickramasinghe K; Long TI; Kurumboor SK; Bernstein L; Peters JH; DeMeester SR; DeMeester TR; Skinner KA; Laird PW
    Cancer Res; 2001 Apr; 61(8):3410-8. PubMed ID: 11309301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma.
    Brabender J; Marjoram P; Lord RV; Metzger R; Salonga D; Vallböhmer D; Schäfer H; Danenberg KD; Danenberg PV; Selaru FM; Baldus SE; Hölscher AH; Meltzer SJ; Schneider PM
    Cancer Epidemiol Biomarkers Prev; 2005 Sep; 14(9):2113-7. PubMed ID: 16172218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular biology of Barrett's adenocarcinoma.
    Wijnhoven BP; Tilanus HW; Dinjens WN
    Ann Surg; 2001 Mar; 233(3):322-37. PubMed ID: 11224619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased expression of epidermal growth factor receptors in Barrett's esophagus associated with alkaline reflux: a putative model for carcinogenesis.
    Jankowski J; Hopwood D; Pringle R; Wormsley KG
    Am J Gastroenterol; 1993 Mar; 88(3):402-8. PubMed ID: 8438848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation.
    Kimchi ET; Posner MC; Park JO; Darga TE; Kocherginsky M; Karrison T; Hart J; Smith KD; Mezhir JJ; Weichselbaum RR; Khodarev NN
    Cancer Res; 2005 Apr; 65(8):3146-54. PubMed ID: 15833844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased CDX2 and decreased PITX1 homeobox gene expression in Barrett's esophagus and Barrett's-associated adenocarcinoma.
    Lord RV; Brabender J; Wickramasinghe K; DeMeester SR; Holscher A; Schneider PM; Danenberg PV; DeMeester TR
    Surgery; 2005 Nov; 138(5):924-31. PubMed ID: 16291394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
    Chatelain D; Fléjou JF
    Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.